Boron-10 carriers and their applications in boron neutron capture therapy

Abstract

Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the ¹⁰B(n,α)⁷Li nuclear reaction with minimal side effects on normal tissues. As a binary, target-specific therapeutic modality for malignancies, BNCT critically depends on novel boron delivery carriers that exhibit high tumor affinity and prolonged intratumoral retention. Although several boron carriers have received Food and Drug Administration approval for clinical investigation, leading carriers such as L-p-boronophenylalanine (BPA) and sodium borocaptate (BSH) continue to require high infusion doses and exhibit limited tumor selectivity and affinity, short systemic half-lives, and limited in vivo stability. These challenges have stimulated extensive global research into novel boron-10 carriers and innovative carrier platforms, including amino acids, sugars, porphyrin derivatives, nucleotides, and a variety of nanocarrier systems. This review provides a systematic classification of high-abundance boron-10 carriers, critically examines radio-boron research, and evaluates the potential integration of BNCT into clinical diagnostics and advanced cancer treatment protocols. By detailing the current status of novel boron-10 carriers, this review further aims to elucidate critical challenges and opportunities in BNCT drug development, ultimately providing a theoretical foundation for next-generation BNCT interventions.

Keywords

Boron neutron capture therapy / boron-10 carrier / high tumor affinity / L-p-boronophenylalanine / sodium borocaptate

References

[1] Barth RF, Coderre JA, Vicente MGH, Blue TEJCCR. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res. 2005; 11(11): 3987-4002.

[2] Barth RF, Vicente MG, Harling OK, et al. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer. Radiat Oncol 2012; 7: 1-21.

[3] He H, Li J, Jiang P, et al. The basis and advances in clinical application of boron neutron capture therapy. Radiat Oncol. 2021; 16(1): 216.

[4] James C. The existence of a neutron. Proc. 1932; 136 (830): 692–708.

[5] Locher GL. Biological effects and therapeutic possibilities of neutrons. Am J Roentgenol Radium Ther. 1936; 36: 1-13.

[6] Asbury AK, Ojemann RG, Nielsen SL, Sweet WHJJoN, Neurology E. Neuropathologic study of fourteen cases of malignant brain tumor treated by boron-10 slow neutron capture radiation. J Neuropathol Exp Neurol. 1972; 31(2): 278-303.

[7] Hatanaka H. Basic and clinical studies on boronneutron capture therapy. Nippon Acta Neuroradiol. 1968; 9: 37-40.

[8] Hatanaka H. Boron-neutron capture therapy for tumors. Glioma.1991: 233-249.

[9] Hatanaka H, Sano K. A revised boron-neutron capture therapy for malignant brain tumours: I. Experience on terminally Ill patients after Co-60 radiotherapy. Z Neurol. 1973; 204: 309-332.

[10] Mishima Y, Honda C, Ichihashi M, et al. Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking 10B-compound. Lancet. 1989; 334(8659): 388-389.

[11] Ishiwata K, Ido T, Mejia AA, et al. Synthesis and radiation dosimetry of 4-borono-2-[18F] fluoro-D, L-phenylalanine: a target compound for PET and boron neutron capture therapy. Appl Radiat Isot.1991; 42(4): 325-328.

[12] Miyatake S-I, Kawabata S, Kajimoto Y, et al. Modified boron neutron capture therapy for malignant gliomas performed using epithermal neutron and two boron compounds with different accumulation mechanisms: an efficacy study based on findings on neuroimages. J Neurosurg. 2005; 103(6): 1000-1009.

[13] Kawabata S, Miyatake SI, Kajimoto Y, et al. The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. J Neurooncol. 2003; 65: 159-165.

[14] Yanagie H, Maruyama S, Oyama K, et al. First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10BPA. In Vivo. 2025; 39(3): 1470-1491.

[15] Smith DR, Chandra S, Barth RF, Yang W, Joel DD, Coderre JAJCr. Quantitative imaging and microlocalization of boron-10 in brain tumors and infiltrating tumor cells by SIMS ion microscopy: relevance to neutron capture therapy. Cancer Res. 2001; 61(22): 8179-8187.

[16] Kankaanranta L, Seppälä T, Koivunoro H, et al. Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2012; 82(1): e67-e75.

[17] Kawabata S, Miyatake SI, Kuroiwa T, et al. Boron neutron capture therapy for newly diagnosed glioblastoma. J Radiat Res. 2009; 50(1): 51-60.

[18] Capoulat ME, Cartelli D, Baldo M, et al. Accelerator-based neutron sources for BNCT. Health Technol. 2024; 14(5): 1007-1015.

[19] Barth RF, Mi P, Yang WJCC. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 2018; 38: 1-15.

[20] Yong Z, Song Z, Zhou Y, et al. Boron neutron capture therapy for malignant melanoma: first clinical case report in China. Chin J Cancer Res. 2016; 28(6): 634-640.

[21] Zhang Z, Yong Z, Jin C, et al. Biodistribution studies of boronophenylalanine in different types of skin melanoma. Appl Radiat Isot. 2020; 163:109215.

[22] Zhang Z, Chong Y, Liu Y, et al. A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China. Cancers (Basel). 2023; 15(16): 4060.

[23] Dai Q, Yang Q, Bao X, Chen J, Han M, Wei QJMP. The development of boron analysis and imaging in boron neutron capture therapy (BNCT). Mol Pharm. 2022; 19(2): 363-377.

[24] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3): 209-249.

[25] Nakagawa Y, Pooh K, Kobayashi T, et al. Clinical review of the Japanese experience with boron neutron capture therapy and a proposed strategy using epithermal neutron beams. J Neurooncol. 2003; 62: 87-99.

[26] Miyatake S-I, Kawabata S, Yokoyama K, et al. Survival benefit of boron neutron capture therapy for recurrent malignant gliomas. J Neurooncol. 2009; 91: 199-206.

[27] Mishima Y.Selective thermal neutron capture therapy of cancer cells using their specific metabolic activities—melanoma as prototype. In: Cancer neutron capture therapy. Springer; 1996: 1-26.

[28] Hiratsuka J, Kamitani N, Tanaka R, et al. Boron neutron capture therapy for vulvar melanoma and genital extramammary Paget's disease with curative responses. Cancer Commun (Lond). 2018; 38(1): 38.

[29] Kankaanranta L, Saarilahti K, Mäkitie A, et al. Boron neutron capture therapy (BNCT) followed by intensity modulated chemoradiotherapy as primary treatment of large head and neck cancer with intracranial involvement. Radiother Oncol. 2011; 99(1): 98-99.

[30] Ariyoshi Y, Miyatake S-I, Kimura Y, et al. Boron neuron capture therapy using epithermal neutrons for recurrent cancer in the oral cavity and cervical lymph node metastasis. Oncol Rep. 2007; 18(4): 861-866.

[31] Kimura Y, Ariyoshi Y, Miyatake S, et al. Boron neutron capture therapy for papillary cystadenocarcinoma in the upper lip: a case report. Int J Oral Maxillofac Surg. 2009; 38(3): 293-295.

[32] Kimura Y, Ariyoshi Y, Shimahara M, et al. Boron neutron capture therapy for recurrent oral cancer and metastasis of cervical lymph node. Appl Radiat Isot. 2009; 67(7-8): S47-S49.

[33] Aihara T, Hiratsuka J, Morita N, et al. First clinical case of boron neutron capture therapy for head and neck malignancies using 18F-BPA PET. Head Neck. 2006; 28(9): 850-855.

[34] Kato I, Ono K, Sakurai Y, et al. Effectiveness of BNCT for recurrent head and neck malignancies. 2004; 61(5): 1069-1073.

[35] Yanagie H, Maruyama S, Oyama K, et al. First Experiences of Pilot Clinical Studies on Boron Neutron Capture Therapy for Recurrent Gastrointestinal Cancers Using an Intravenous Injection of 10BPA. In Vivo. 2025; 39(3): 1470-1491.

[36] Monti Hughes A, Hu N. Optimizing boron neutron capture therapy (BNCT) to treat cancer: an updated review on the latest developments on boron compounds and strategies. Cancers. 2023; 15(16): 4091.

[37] Mohan R, Grosshans D. Proton therapy–present and future. Adv Drug Deliv Rev. 2017; 109: 26-44.

[38] Lin B, Gao F, Yang Y, et al. FLASH radiotherapy: history and future. Front Oncol. 2021; 11:644400.

[39] Barth RF, Grecula JCJAR, Isotopes. Boron neutron capture therapy at the crossroads-Where do we go from here? Appl Radiat Isot. 2020; 160:109029.

[40] FARR LE, SWEET WH, ROBERTSON JS, et al. Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am J Roentgenol Radium Ther Nucl Med. 1954; 71(2): 279-293.

[41] Kabalka GW, Wu Z, Yao MLJAOC. Synthesis of a series of boronated unnatural cyclic amino acids as potential boron neutron capture therapy agents. Cheminform. 2008; 22(9): 516-522.

[42] Hatanaka H, Sano K, Yasukochi HJPinctfc. Clinical results of boron neutron capture therapy. 1992: 561-568.

[43] Coghi P, Li J, Hosmane NS, Zhu YJMRR. Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment. Med Res Rev. 2023; 43(5): 1809-1830.

[44] Dymova MA, Taskaev SY, Richter VA, Kuligina EV. Boron neutron capture therapy: Current status and future perspectives. Cancer Commun. 2020; 40(9): 406-421.

[45] Snyder H, Reedy AJ, Lennarz WJJJotACS. Synthesis of aromatic boronic acids. aldehydo boronic acids and a boronic acid analog of tyrosine1. J Am Chem Soc. 1958; 80(4): 835-838.

[46] Mishima Y, Ichihashi M, Hatta S, et al. First human clinical trial of melanoma neutron capture. Diagn Ther. 1989; 165(2-3): 251-254.

[47] Yoshino K, Suzuki A, Mori Y, et al. Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlenther Onkol. 1989; 165(2-3): 127-129.

[48] Coderre JA, Glass JD, Fairchild RG, Micca PL, Fand I, Joel DD JCr. Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma. Cancer Res. 1990; 50(1): 138-141.

[49] Chanana AD, Capala J, Chadha M, et al. Boron neutron capture therapy for glioblastoma multiforme: interim results from the phase I/II dose-escalation studies. Neurosurgery. 1999; 44(6): 1182-1192.

[50] Sköld K, H-Stenstam B, Diaz A, Giusti V, Pellettieri L, Hopewell JJANS. Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f. Acta Neurol Scand. 2010; 122(1): 58-62.

[51] Kankaanranta L, Seppälä T, Koivunoro H, et al. L-boronophenylalanine-mediated boron neutron capture therapy for malignant glioma progressing after external beam radiation therapy: a Phase I study. Int J Radiat Oncol Biol Phys. 2011; 80(2): 369-376.

[52] Dai L, Liu J, Yang T, et al. Lipoic acid-boronophenylalanine-derived multifunctional vesicles for cancer chemoradiotherapy. Nat Commun. 2025; 16(1): 1329.

[53] Soloway A, Hatanaka H, Davis MJJomc. Penetration of brain and brain tumor. VII. Tumor-binding sulfhydryl boron compounds. J Med Chem. 1967; 10(4): 714-717.

[54] Hatanaka H, Nakagawa YJIJoROBP. Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int J Radiat Oncol Biol Phys. 1994; 28(5): 1061-1066.

[55] Ono K, Masunaga S-I, Kinashi Y, et al. Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy. Int J Radiat Oncol Biol Phys. 1996; 34(5): 1081-1086.

[56] Yang W, Barth RF, Rotaru JH, et al. Enhanced survival of glioma bearing rats following boron neutron capture therapy with blood-brain barrier disruption and intracarotid injection of boronophenylalanine. J Neurooncol. 1997; 33: 59-70.

[57] Barth RF, Yang W, Rotaru JH, et al. Boron neutron capture therapy of brain tumors: enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res. 1997; 57(6): 1129-1136.

[58] Burgess A, Shah K, Hough O, Hynynen KJEron. Focused ultrasound-mediated drug delivery through the blood–brain barrier. Expert Rev Neurother. 2015; 15(5): 477-491.

[59] Imahori Y, Ueda S, Ohmori Y, et al. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma. J Nucl Med. 1998; 39(2): 325-333.

[60] Mori Y, Suzuki A, Yoshino K, Kakihana H. Complex formation of p-boronophenylalanine with some monosaccharides. Pigment Cell Res. 1989; 2(4): 273-277.

[61] Chadha M, Capala J, Coderre JA, et al. Boron neutron-capture therapy (BNCT) for glioblastoma multiforme (GBM) using the epithermal neutron beam at the Brookhaven National Laboratory. Int J Radiat Oncol Biol Phys. 1998; 40(4): 829-834.

[62] Diaz AZJJon-o. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neurooncol. 2003; 62: 101-109.

[63] Kankaanranta L, Koivunoro H, Kortesniemi M, et al. BPA-Based BNCT in the treatment of glioblastoma multiforme: A dose escalation study. ENEA; 2008:

[64] Hopewell J, Gorlia T, Pellettieri L, et al. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential. Appl Radiat Isot. 2011; 69(12): 1737-1740.

[65] Kageji T, Mizobuchi Y, Nagahiro S, Nakagawa Y, Kumada HJAR, Isotopes. Long-survivors of glioblatoma treated with boron neutron capture therapy (BNCT). Appl Radiat Isot. 2011; 69(12): 1800-1802.

[66] Miyatake S-I, Tamura Y, Kawabata S, Iida K, Kuroiwa T, Ono KJN. Boron neutron capture therapy for malignant tumors related to meningiomas. Neurosurgery. 2007; 61(1): 82-91.

[67] Nomoto T, Yao Y, Inoue Y, et al. Fructose-functionalized polymers to enhance therapeutic potential of p-boronophenylalanine for neutron capture therapy. J Control Release. 2021; 332: 184-193.

[68] Marfavi A, Kavianpour P, Rendina LMJNRC. Carboranes in drug discovery, chemical biology and molecular imaging. Nat Rev Chem. 2022; 6(7): 486-504.

[69] Gabel D, Moller D, Harfst S, Roesler J, Ketz HJIC. Synthesis of S-alkyl and S-acyl derivatives of mercaptoundecahydrododecaborate, a possible boron carrier for neutron capture therapy. Inorg Chem. 1993; 32(11): 2276-2278.

[70] Koganei H, Ueno M, Tachikawa S, et al. Development of high boron content liposomes and their promising antitumor effect for neutron capture therapy of cancers. Bioconjug Chem. 2013; 24(1): 124-132.

[71] El-Zaria ME, Ban HS, Nakamura HJCAEJ. Boron-containing protoporphyrin IX derivatives and their modification for boron neutron capture therapy: synthesis, characterization, and comparative in vitro toxicity evaluation. Chemistry. 2010; 16(5): 1543-1552.

[72] Lechtenberg B, Gabel D. Synthesis of a (B12H11S) 2− containing glucuronoside as potential prodrug for BNCT. J Organomet Chem. 2005; 690(11): 2780-2782.

[73] Ratajski M, Osterloh J, Gabel DJA-CAiMC. Boron-containing chlorins and tetraazaporphyrins: synthesis and cell uptake of boronated pyropheophorbide a derivatives. Anticancer Agents Med Chem. 2006; 6(2): 159-166.

[74] Lee J-D, Ueno M, Miyajima Y, Nakamura HJOl. Synthesis of boron cluster lipids: closo-dodecaborate as an alternative hydrophilic function of boronated liposomes for neutron capture therapy. Org Lett. 2007; 9(2): 323-326.

[75] Justus E, Awad D, Hohnholt M, et al. Synthesis, liposomal preparation, and in vitro toxicity of two novel dodecaborate cluster lipids for boron neutron capture therapy. Bioconjug Chem. 2007; 18(4): 1287-1293.

[76] Koo M-S, Ozawa T, Santos RA, et al. Synthesis and comparative toxicology of a series of polyhedral borane anion-substituted tetraphenyl porphyrins. J Med Chem. 2007; 50(4): 820-827.

[77] Genady AR, Ioppolo JA, Azaam MM, Mohamed EJEJoMC. New functionalized mercaptoundecahydrododecaborate derivatives for potential application in boron neutron capture therapy: Synthesis, characterization and dynamic visualization in cells. Eur J Med Chem. 2015; 93: 574-583.

[78] Kabalka GW, Das BC, Das SJTL. Synthesis of novel boron containing unnatural cyclic amino acids as potential therapeutic agents. Tetrahedron Lett. 2001; 42(41): 7145-7146.

[79] Kabalka G, Wu Z, Yao M, Natarajan NJAr, isotopes. The syntheses and in vivo biodistribution of novel boronated unnatural amino acids. Appl Radiat Isot. 2004; 61(5): 1111-1115.

[80] Li J, Shi Y, Zhang Z, et al. A metabolically stable boron-derived tyrosine serves as a theranostic agent for positron emission tomography guided boron neutron capture therapy. Bioconjug Chem. 2019; 30(11): 2870-2878.

[81] Li X, Tian Y, Yang Y-X, et al. Life course adiposity and Alzheimer's disease: A Mendelian randomization study. J Alzheimers Dis. 2021; 82(2): 503-512.

[82] Lindström P, Naeslund C, Sjöberg SJTL. Enantioselective synthesis and absolute configurations of the enantiomers of o-carboranylalanine. Tetrahedron Lett. 2000; 41(5): 751-754.

[83] Radel PA, Kahl SBJTJoOC. Enantioselective synthesis of L-and D-carboranylalanine. J Org Chem. 1996; 61(14): 4582-4588.

[84] Malan C, Morin CJTJoOC. A concise preparation of 4-borono-L-phenylalanine (L-BPA) from L-phenylalanine. J Org Chem. 1998; 63(22): 8019-8020.

[85] Nakamura H, Fujiwara M, Yamamoto YJFiNCTV. A concise synthesis of enantiomerically pure L-(4-Boronophenyl) alanine from L-tyrosine. J Org Chem. 2001: 765-768.

[86] Masunaga S-i, Ono K, Kirihata M, et al. Potential of α-amino alcohol p-boronophenylalaninol as a boron carrier in boron neutron capture therapy, regarding its enantiomers. J Cancer Res Clin Oncol. 2003; 129: 21-28.

[87] Li R, Zhang J, Guo J, et al. Application of Nitroimidazole–Carbobane-Modified Phenylalanine Derivatives as Dual-Target Boron Carriers in Boron Neutron Capture Therapy. Mol Pharm. 2019; 17(1): 202-211.

[88] Dı́az S, González A, de Riancho SG, Rodrı́guez AJJoOC. Boron complexes of S-trityl-L-cysteine and S-tritylglutathione. J Org Chem. 2000; 610(1-2): 25-30.

[89] He T, Chittur SV, Musah RAJACN. Impact on glioblastoma U87 cell gene expression of a carborane cluster-bearing amino acid: Implications for carborane toxicity in mammalian cells. ACS Chem Neurosci. 2018; 10(3): 1524-1534.

[90] He T, Musah RAJAO. Evaluation of the Potential of 2-Amino-3-(1, 7-dicarba-closo-dodecaboranyl-1-thio) propanoic acid as a boron neutron capture therapy agent. ACS Omega. 2019; 4(2): 3820-3826.

[91] Chio CM, Huang YC, Chou YC, Hsu FC, Lai YB, Yu C-SJAMCL. Boron accumulation in brain tumor cells through boc-protected tryptophan as a carrier for boron neutron capture therapy. ACS Med Chem Lett. 2020; 11(4): 589-596.

[92] Aoyagi M, Agranoff BW, Washburn LC, Smith QRJJon. Blood-brain barrier transport of 1-aminocyclohexanecarboxylic acid, a nonmetabolizable amino acid for in vivo studies of brain transport. J Neurochem. 1988; 50(4): 1220-1226.

[93] Nichols TL, Kabalka GW, Miller LF, Khan MK, Smith GTJMP. Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography. Med Phys. 2002; 29(10): 2351-2358.

[94] Hübner K, Thie J, Smith G, et al. Positron emission tomography (PET) with 1-aminocyclobutane-1-[11C] carboxylic acid (1-[11C]-ACBC) for detecting recurrent brain tumors. Clin Positron Imaging. 1998; 1(3): 165-173.

[95] Hasabelnaby S, Goudah A, Agarwal HK, Tjarks WJEjomc. Synthesis, chemical and enzymatic hydrolysis, and aqueous solubility of amino acid ester prodrugs of 3-carboranyl thymidine analogs for boron neutron capture therapy of brain tumors. Eur J Med Chem. 2012; 55: 325-334.

[96] Mező G, Manea MJEoodd. Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv. 2010; 7(1): 79-96.

[97] Michel MC, Beck-Sickinger A, Cox H, et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. 1998; 50(1): 143-150.

[98] Lindner D, Stichel J, Beck-Sickinger AGJN. Molecular recognition of the NPY hormone family by their receptors.Nutrition. 2008; 24(9): 907-917.

[99] Worm DJ, Hoppenz P, Els-Heindl S, et al. Selective neuropeptide Y conjugates with maximized carborane loading as promising boron delivery agents for boron neutron capture therapy. J Med Chem. 2019; 63(5): 2358-2371.

[100] Nagai A, Nagai Y, Qu H, Zhang S. Dynamic behaviors of lipid-like self-assembling peptide A6D and A6K nanotubes. J Nanosci Nanotechnol. 2007; 7(7): 2246-2252.

[101] Yoshida D, Kim K, Takumi I, Yamaguchi F, Adachi K, Teramoto A. A transfection method for short interfering RNA with the lipid-like self-assembling nanotube, A6K. Med Mol Morphol. 2013; 46(2): 86-91.

[102] Michiue H, Kitamatsu M, Fukunaga A, et al. Self-assembling A6K peptide nanotubes as a mercaptoundecahydrododecaborate (BSH) delivery system for boron neutron capture therapy (BNCT). J Control Release. 2021; 330: 788-796.

[103] Michiue H, Sakurai Y, Kondo N, et al. The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide. Biomaterials. 2014; 35(10): 3396-3405.

[104] Nakase I, Katayama M, Hattori Y, et al. Intracellular target delivery of cell-penetrating peptide-conjugated dodecaborate for boron neutron capture therapy (BNCT). Chem Commun (Camb). 2019; 55(93): 13955-13958.

[105] Quan H, Fan L, Huang Y, et al. Hyaluronic acid-decorated carborane-TAT conjugation nanomicelles: a potential boron agent with enhanced selectivity of tumor cellular uptake. Colloids Surf B Biointerfaces. 2021; 204:111826.

[106] Chen J, Yang Q, Liu M, et al. Remarkable boron delivery of iRGD-modified polymeric nanoparticles for boron neutron capture therapy. Int J Nanomedicine. 2019: 8161-8177.

[107] Yang Q, Dai Q, Bao X, et al. Evaluation of a tumor-targeting oligosaccharide nanosystem in BNCT on an orthotopic hepatocellular carcinoma model. Mol Pharm. 2022; 20(2): 1025-1038.

[108] Chen J, Dai Q, Yang Q, et al. Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma. J Nanobiotechnology. 2022; 20(1): 102.

[109] Matteson D, Cheng T-CJTJoOC. Displacement reactions of dibutyl iodomethaneboronate and the synthesis of boron-substituted pyrimidines. J Org Chem. 1968; 33(8): 3055-3060.

[110] Dewar M, Maitlis PJJotACS. A boron-containing purine analog. J Am Chem Soc. 1959; 81(23): 6329-6330.

[111] Soloway A, Zhuo J-C, Rong F-G, et al. Identification, development, synthesis and evaluation of boron-containing nucleosides for neutron capture therapy. Opt Commun. 1999; 581(1-2): 150-155.

[112] Lesnikowski Z, Schinazi RJPJoC. Boron neutron capture therapy of causes: nucleic bases, nucleosides, oligonucleotides as potential boron carries. Pol J Chem. 1995; 69: 827-840.

[113] Al-Nabulsi I, Takamiya Y, Voloshin Y, Dritschilo A, Martuza RL, Jorgensen TJJCr. Expression of thymidine kinase is essential to low dose radiation resistance of rat glioma cells. Cancer Res. 1994; 54(21): 5614-5617.

[114] Persson L, Boethius J, Gronowitz JS, Källander C, Lindgren LJJon. Thymidine kinase in brain-tumor cysts. J Neurosurg. 1985; 63(4): 568-572.

[115] Peters T jr. All about albumin: biochemistry, genetics, and medical applications. Academic press; 1995.

[116] Fanali G, Di Masi A, Trezza V, Marino M, Fasano M, Ascenzi PJMaom. Human serum albumin: from bench to bedside. Mol Aspects Med. 2012; 33(3): 209-290.

[117] Matsumura Y, Maeda HJCr. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12_Part_1): 6387-6392.

[118] Maeda H, Wu J, Sawa T, Matsumura Y, Hori KJJocr. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2): 271-284.

[119] Kikuchi S, Kanoh D, Sato S, Sakurai Y, Suzuki M, Nakamura HJJoCR. Maleimide-functionalized closo-dodecaborate albumin conjugates (MID-AC): Unique ligation at cysteine and lysine residues enables efficient boron delivery to tumor for neutron capture therapy. J Control Release. 2016; 237: 160-167.

[120] Magnusson G, Chernyak AY, Kihlberg J, et al. Neoglycoconjugates. 1994: 53-143.

[121] Marepally SR, Yao M-L, Kabalka GW. Boronated carbohydrate derivatives as potential boron neutron capture therapy reagents. Future Med Chem. 2013; 5(6): 693-704.

[122] Orlova A, Zinin A, Malysheva N, Kononov L, Sivaev I, Bregadze VJRcb. Conjugates of polyhedral boron compounds with carbohydrates 1. New approach to the design of selective agents for boron neutron capture therapy of cancer. Russ Chem Bull. 2003; 52(12): 2766-2768.

[123] Lai CH, Lin YC, Chou FI, et al. Design of multivalent galactosyl carborane as a targeting specific agent for potential application to boron neutron capture therapy. Chem Commun (Camb). 2012; 48(4): 612-614

[124] Zhang T, Li G, Li S, et al. Asialoglycoprotein receptor targeted micelles containing carborane clusters for effective boron neutron capture therapy of hepatocellular carcinoma.Colloids Surf B Biointerfaces. 2019; 182:110397.

[125] Yates MK, Seley-Radtke KL. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold. Antiviral research. 2019; 162: 5-21.

[126] Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antivir Res. 2018; 154: 66-86.

[127] Yoshida Y, Honma M, Kimura Y, Abe H. Structure, synthesis and inhibition mechanism of nucleoside analogues as HIV-1 reverse transcriptase inhibitors (NRTIs). ChemMedChem. 2021; 16(5): 743-766.

[128] Cerecetto H, Couto MJG-CD, Approaches T. Medicinal chemistry of boron-bearing compounds for BNCT-glioma treatment: Current challenges and perspectives. 2018;

[129] Novopashina DS, Vorobyeva MA, Venyaminova AJFiC. Recent advances in the synthesis of high boron-loaded nucleic acids for BNCT. Front Chem. 2021; 9:619052.

[130] Chen X, Bastow K, Goz B, Kucera L, Morris-Natschke S, Ishaq K. Boronic acid derivatives targeting HIV-1. Antiviral Chemistry and Chemotherapy. 1996; 7(2): 108-114.

[131] El Amri C, Martin AR, Vasseur JJ, Smietana M. Borononucleotides as substrates/binders for human NMP kinases: enzymatic and spectroscopic evaluation. ChemBioChem. 2012; 13(11): 1605-1612.

[132] Uram Ł, Nizioł J, Maj P, et al. N (4)-[B-(4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan) methyl]-2′-deoxycytidine as a potential boron delivery agent with respect to glioblastoma. Biomed. Pharmacother. 2017; 95: 749-755.

[133] Vicente MJCMC-A-CA. Porphyrin-based sensitizers in the detection and treatment of cancer: recent progress. Curr Med Chem Anticancer Agents. 2001; 1(2): 175-194.

[134] Dolmans DE, Fukumura D, Jain RKJNrc. Photodynamic therapy for cancer. Nat Rev Cancer. 2003; 3(5): 380-387.

[135] Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998; 90(12): 889-905.

[136] Kahl S, Joel D, Nawrocky M, et al. Uptake of a nido-carboranylporphyrin by human glioma xenografts in athymic nude mice and by syngeneic ovarian carcinomas in immunocompetent mice. Proc Natl Acad Sci U S A. 1990; 87(18): 7265-7269.

[137] Kahl SB, Koo M-SJJotCS, Chemical Communications. Synthesis of tetrakis-carborane-carboxylate esters of 2, 4-bis-(α, β-dihydroxyethyl)-deuteroporphyrin IX. J Chem Soc Chem Commun. 1990;(24): 1769-1771.

[138] Miura M, Gabel D, Oenbrink G, Fairchild RGJTl. Preparation of carboranyl porphyrins for boron neutron capture therapy. Tetrahedron Lett. 1990; 31(16): 2247-2250.

[139] Shi Y, Li J, Zhang Z, et al. Tracing boron with fluorescence and PET imaging of boronated porphyrin nanocomplex for imaging guided boron neutron capture therapy. ACS Appl Mater Interfaces. 2018; 10: 43387-43395.

[140] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2(12): 751-760.

[141] Wang AZ, Langer R, Farokhzad OCJArom. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012; 63(1): 185-198.

[142] Jain RK, Stylianopoulos TJNrCo. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010; 7(11): 653-664.

[143] Brannon-Peppas L, Blanchette JOJAddr. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev. 2004; 56(11): 1649-1659.

[144] Shi J, Kantoff PW, Wooster R, Farokhzad OCJNrc. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17(1): 20-37.

[145] Maeda HJAier. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41(1): 189-207.

[146] Zhang L, Gu F, Chan J, et al. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 2008; 83(5): 761-769.

[147] Ahmad F. Boron Nanocomposites for Boron Neutron Capture Therapy and in Biomedicine: Evolvement and Challenges. Biomaterials Research. 2025; 29: 0145.

[148] Gao S, Fu R, Hosmane NSJP, Chemistry A. Nanomaterials for boron and gadolinium neutron capture therapy for cancer treatment. Pure Appl Chem. 2015; 87(2): 123-134.

[149] Zhu Y, Hosmane NSJP, Chemistry A. Nanostructured boron compounds for cancer therapy. Pure Appl Chem. 2018; 90(4): 653-663.

[150] Hu K, Yang Z, Zhang L, et al. Boron agents for neutron capture therapy. Coord Chem Rev. 2020; 405:213139.

[151] Kawasaki R, Hirano H, Yamana K, et al. Carborane bearing pullulan nanogel-boron oxide nanoparticle hybrid for boron neutron capture therapy. Nanomedicine. 2023; 49:102659.

[152] Nomoto T, Inoue Y, Yao Y, et al. Poly (vinyl alcohol) boosting therapeutic potential of p-boronophenylalanine in neutron capture therapy by modulating metabolism. Sci Adv. 2020; 6(4):eaaz1722.

[153] Takeuchi I, Nomura K, Makino KJC, Biointerfaces SB. Hydrophobic boron compound-loaded poly (l-lactide-co-glycolide) nanoparticles for boron neutron capture therapy. Colloids Surf B Biointerfaces. 2017; 159: 360-365.

[154] Meher N, Seo K, Wang S, et al. Synthesis and preliminary biological assessment of carborane-loaded theranostic nanoparticles to target prostate-specific membrane antigen. ACS Appl Mater Interfaces. 2021; 13(46): 54739-54752.

[155] Achilli C, Grandi S, Ciana A, et al. Biocompatibility of functionalized boron phosphate (BPO4) nanoparticles for boron neutron capture therapy (BNCT) application. Nanomedicine. 2014; 10(3): 589-597.

[156] Ciofani G, Raffa V, Menciassi A, Cuschieri AJNrl. Folate functionalized boron nitride nanotubes and their selective uptake by glioblastoma multiforme cells: implications for their use as boron carriers in clinical boron neutron capture therapy. Nanoscale Res Lett. 2009; 4: 113-121.

[157] Yang X, Grailer JJ, Pilla S, Steeber DA, Gong SJBc. Tumor-targeting, pH-responsive, and stable unimolecular micelles as drug nanocarriers for targeted cancer therapy. Bioconjug Chem. 2010; 21(3): 496-504.

[158] Morelli C, Maris P, Sisci D, et al. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells. Nanoscale. 2011; 3(8): 3198-3207.

[159] Chang EF, Zada G, Kim S, et al. Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg. 2008; 108(4): 736-745.

[160] Losa M, Picozzi P, Motta M, Valle M, Franzin A, Mortini PJJoEI. The role of radiation therapy in the management of non-functioning pituitary adenomas. J Endocrinol Invest. 2011; 34: 623-629.

[161] Pollock BE, Cochran J, Natt N, et al. Gamma knife radiosurgery for patients with nonfunctioning pituitary adenomas: results from a 15-year experience. Int J Radiat Oncol Biol Phys. 2008; 70(5): 1325-1329.

[162] FeiGl GC, PistraCher K, Berghold A, Mokry MJJon. Pituitary insufficiency as a side effect after radiosurgery for pituitary adenomas: the role of the hypothalamus. J Neurosurg. 2010; 113 (Special_Supplement): 153-159.

[163] Dai C, Cai F, Hwang KC, et al. Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas. Sci China Life Sci. 2013; 56: 163-173.

[164] Dai L, Liu J, Zhao X, et al. BPA-Containing Polydopamine Nanoparticles for Boron Neutron Capture Therapy in a U87 Glioma Orthotopic Model. Advanced Functional Materials. 2023; 33(23):2214145.

[165] Ciofani G, Danti S, Genchi GG, Mazzolai B, Mattoli VJS. Boron nitride nanotubes: Biocompatibility and potential spill-over in nanomedicine. Small. 2013; 9(9-10): 1672-1685.

[166] Lee CH, Bhandari S, Tiwari B, Yapici N, Zhang D, Yap YKJM. Boron nitride nanotubes: recent advances in their synthesis, functionalization, and applications. Molecules. 2016; 21(7): 922.

[167] Sukhorukova IV, Zhitnyak IY, Kovalskii AM, et al. Boron nitride nanoparticles with a petal-like surface as anticancer drug-delivery systems. ACS Appl Mater Interfaces. 2015; 7(31): 17217-17225.

[168] Li L, Li J, Shi Y, et al. On-demand biodegradable boron nitride nanoparticles for treating triple negative breast cancer with boron neutron capture therapy. ACS Nano. 2019; 13(12): 13843-13852.

[169] Kresge C, Leonowicz ME, Roth WJ, Vartuli J, Beck JJn. Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism. Nature. 1992; 359(6397): 710-712.

[170] Vallet-Regi M, Rámila A, Del Real R, Pérez-Pariente JJCoM. A new property of MCM-41: drug delivery system. Chem Mater. 2001; 13(2): 308-311.

[171] Beck J, Vartuli J, Roth W, et al. A New Family of Mesoporous Molecular Sieves Prepared with Liquid Crystal Templates. Journal of the American Chemical Society, 1992; 114(10): 834.

[172] Trewyn BG, Slowing II, Giri S, Chen H-T, Lin VS-YJAocr. Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol–gel process and applications in controlled release. Acc Chem Res. 2007; 40(9): 846-853.

[173] Hurley MT, Wang Z, Mahle A, et al. Synthesis, characterization, and application of antibody functionalized fluorescent silica nanoparticles.Adv Funct Mater. 2013; 23(26): 3335-3343.

[174] Lai CH, Lai NC, Chuang YJ, Chou FI, Yang CM, Lin CC. Trivalent galactosyl-functionalized mesoporous silica nanoparticles as a target-specific delivery system for boron neutron capture therapy. Nanoscale. 2013; 5(19): 9412-9418.

[175] Vares G, Jallet V, Matsumoto Y, et al. Functionalized mesoporous silica nanoparticles for innovative boron-neutron capture therapy of resistant cancers. Nanomedicine. 2020; 27:102195.

[176] Ciani L, Bortolussi S, Postuma I, et al. Rational design of gold nanoparticles functionalized with carboranes for application in Boron Neutron Capture Therapy. Int J Pharm. 2013; 458(2): 340-346.

[177] Wu CY, Lin JJ, Chang WY, et al. Development of theranostic active-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT). Colloids Surf B Biointerfaces. 2019; 183:110387.

[178] Pulagam KR, Henriksen-Lacey M, B Uribe K, et al. In vivo evaluation of multifunctional gold nanorods for boron neutron capture and photothermal therapies. ACS Appl Mater Interfaces. 2021; 13(42): 49589-49601.

[179] Wang Z, Chen Z, Zhang Z, et al. Multifunctional high boron content MOFs nano-co-crystals for precise boron neutron capture therapy for brain glioma in situ. Nano Today. 2022; 45:101558.

[180] Wang Z, Lei R, Zhang Z, et al. Boron-Containing MOF Nanoparticles with Stable Metabolism in U87-MG Cells Combining Microdosimetry To Evaluate Relative Biological Effectiveness of Boron Neutron Capture Therapy. ACS Appl Mater Interfaces. 2024; 16(3): 3232-3242.

[181] Li J, Kong J, Ma S, et al. Exosome-coated 10b carbon dots for precise boron neutron capture therapy in a mouse model of glioma in situ. Adv Funct Mater. 2021; 31(24):2100969.

[182] Nakamura HJMie. Liposomal boron delivery for neutron capture therapy. Methods Enzymol. 2009; 465: 179-208.

[183] Feakes DA, Shelly K, Hawthorne MFJPotNAoS. Selective boron delivery to murine tumors by lipophilic species incorporated in the membranes of unilamellar liposomes. Proc Natl Acad Sci U S A. 1995; 92(5): 1367-1370.

[184] Peacock G, Ji B, Wang C, Lu DJDD. Cell culture studies of a carborane cholesteryl ester with conventional and PEG liposomes. Drug Deliv. 2003; 10(1): 29-34.

[185] Miyajima Y, Nakamura H, Kuwata Y, et al. Transferrin-loaded nido-carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy. Bioconjug Chem. 2006; 17(5): 1314-1320.

[186] Li J, Sun Q, Lu C, et al. Boron encapsulated in a liposome can be used for combinational neutron capture therapy. Nat Commun. 2022; 13(1): 2143.

[187] Altieri S, Balzi M, Bortolussi S, et al. Carborane derivatives loaded into liposomes as efficient delivery systems for boron neutron capture therapy. J Med Chem. 2009; 52(23): 7829-7835.

[188] Tachikawa S, Miyoshi T, Koganei H, et al. Spermidinium closo-dodecaborate-encapsulating liposomes as efficient boron delivery vehicles for neutron capture therapy. Chem Commun (Camb). 2014; 50(82): 12325-12328.

[189] Wei Q, Kullberg EB, Gedda LJIjoo. Trastuzumab-conjugated boron-containing liposomes for tumor-cell targeting; development and cellular studies. Int J Oncol. 2003; 23(4): 1159-1165.

[190] Kullberg EB, Wei Q, Capala J, Giusti V, Malmström P-U, Gedda LJIjorb. EGF-receptor targeted liposomes with boronated acridine: growth inhibition of cultured glioma cells after neutron irradiation. Int J Radiat Biol. 2005; 81(8): 621-629.

[191] Li L, Dai K, Li J, et al. A Boron-10 nitride nanosheet for combinational boron neutron capture therapy and chemotherapy of tumor. Biomaterials. 2021; 268:120587.

[192] Chen K, Liu S, Lv L, et al. Well-established immunotherapy with R837-loaded boron neutron capture-shocked tumor cells. Nano Today. 2023; 52:101995.

[193] Shi Y, Fu Q, Li J, et al. Covalent organic polymer as a carborane carrier for imaging-facilitated boron neutron capture therapy. ACS Appl Mater Interfaces. 2020; 12(50): 55564-55573.

[194] Mima H, Yamamoto S, Ito M, et al. Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin–conjugated HVJ envelope vector. Mol Cancer Ther. 2006; 5(4): 1021-1028.

[195] Kawaguchi Y, Miyamoto Y, Inoue T, Kaneda YJIjoc. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int J Cancer. 2009; 124(10): 2478-2487.

[196] Kurooka M, Kaneda YJCr. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 2007; 67(1): 227-236.

[197] Yoneoka S, Nakagawa Y, Uto K, et al. Boron-incorporating hemagglutinating virus of Japan envelope (HVJ-E) nanomaterial in boron neutron capture therapy. Sci Technol Adv Mater. 2019; 20(1): 291-304.

[198] Shi Y, Guo Z, Fu Q, et al. Localized nuclear reaction breaks boron drug capsules loaded with immune adjuvants for cancer immunotherapy. Nat Commun. 2023; 14(1): 1884.

[199] Grimes RNJJoce. Boron clusters come of age. 2004; 81(5): 657.

[200] Kaplánek R, Martásek P, Grüner B, et al. Nitric oxide synthases activation and inhibition by metallacarborane-cluster-based isoform-specific affectors. J Med Chem. 2012; 55(22): 9541-9548.

[201] Toppino A, Bova ME, Geninatti Crich S, et al. A carborane-derivative “Click” reaction under heterogeneous conditions for the synthesis of a promising lipophilic MRI/GdBNCT agent. Chemistry. 2013; 19(2): 721-728.

[202] Paulus F, Heusel C, Jaspers M, et al. closo-Carboranyl Analogs of β-Arylethylamines: Direct Synthesis from Alkenes via EnT-Catalysis. Angewandte Chemie International Edition. 2025: e202504793.

[203] Hall DG. Structure, properties, and preparation of boronic acid derivatives. Overview of their reactions and applications. 2005: 1-99.

[204] Yang W, Gao X, Wang B. Biological and medicinal applications of boronic acids. 2005: 481-512.

[205] Plescia J, Moitessier NJEjomc. Design and discovery of boronic acid drugs. Eur J Med Chem. 2020; 195:112270.

[206] Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998; 8(4): 333-338.

[207] Albers HM, Dong A, van Meeteren LA, et al. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A. 2010; 107(16): 7257-7262.

[208] Yang W, Gao X, Wang BJMrr. Boronic acid compounds as potential pharmaceutical agents. Med Res Rev. 2003; 23(3): 346-368.

[209] Yang C, Gonzalez-Angulo A, Reuben J, et al. Bortezomib (VELCADE®) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol. 2006; 17(5): 813-817.

[210] Engel RH, Brown JA, Von Roenn JH, et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest. 2007; 25(8): 733-737.

[211] Sall DJ, Bailey DL, Bastian JA, et al. Diamino benzo [b] thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Potency, efficacy, and pharmacokinetic properties of modified C-3 side chain derivatives. J Med Chem. 2000; 43(4): 649-663.

[212] Kim A, Suzuki Y, Nagasaki YJAB. Molecular design of a high-performance polymeric carrier for delivery of a variety of boronic acid-containing drugs. Acta Biomater. 2021; 121: 554-565.

[213] Kabatas S, Agüi-Gonzalez P, Saal KA, et al. Boron-Containing Probes for Non-optical High-Resolution Imaging of Biological Samples. Angew Chem Int Ed Engl. 2019; 58(11): 3438-3443.

[214] Geninatti-Crich S, Alberti D, Szabo I, et al. MRI-guided neutron capture therapy by use of a dual gadolinium/boron agent targeted at tumour cells through upregulated low-density lipoprotein transporters. Chemistry. 2011; 17(30): 8479-8486.

[215] Mishiro K, Imai S, Ematsu Y, et al. RGD peptide-conjugated dodecaborate with the Ga-DOTA complex: a preliminary study for the development of theranostic agents for boron neutron capture therapy and its companion diagnostics. J Med Chem. 2022; 65(24): 16741-16753.

[216] He J, Li Z, Dhawan G, et al. Fluorine-containing drugs approved by the FDA in 2021.Chin Chem Lett. 2023; 34(1):107578.

[217] Han J, Remete AM, Dobson LS, et al. Next generation organofluorine containing blockbuster drugs. J Fluorine Chem. 2020; 239:109639.

[218] Inoue M, Sumii Y, Shibata N. Contribution of organofluorine compounds to pharmaceuticals. ACS omega. 2020; 5(19): 10633-10640.

[219] Gillis EP, Eastman KJ, Hill MD, Donnelly DJ, Meanwell NA. Applications of fluorine in medicinal chemistry. J Med Chem. 2015; 58(21): 8315-8359.

[220] Han J, Kiss L, Mei H, et al. Chemical aspects of human and environmental overload with fluorine. Chem Rev. 2021; 121(8): 4678-4742.

[221] Jin C, Luo X, Li X, et al. Positron emission tomography molecular imaging-based cancer phenotyping. Cancer. 2022; 128(14): 2704-2716.

[222] Goud NS, Joshi RK, Bharath RD, Kumar P. Fluorine-18: A radionuclide with diverse range of radiochemistry and synthesis strategies for target based PET diagnosis. Eur J Med Chem. 2020; 187:111979.

[223] Zhang M, Li S, Zhang H, Xu H. Research progress of 18F labeled small molecule positron emission tomography (PET) imaging agents. Eur J Med Chem. 2020; 205:112629.

[224] Ford EC, Herman J, Yorke E, Wahl RL. 18F-FDG PET/CT for image-guided and intensity-modulated radiotherapy. J Nucl Med. 2009; 50(10): 1655-1665.

[225] O'Neill H, Malik V, Johnston C, Reynolds JV, O'Sullivan J. Can the efficacy of [18F] FDG-PET/CT in clinical oncology be enhanced by screening biomolecular profiles? Pharmaceuticals. 2019; 12(1): 16.

[226] Kong Z, Li Z, Chen J, et al. A histogram of [18F] BBPA PET imaging differentiates non-neoplastic lesions from malignant brain tumors. EJNMMI Res. 2024; 14(1): 12.

[227] Li Z, Chen J, Kong Z, et al. A bis-boron boramino acid PET tracer for brain tumor diagnosis. Eur J Nucl Med Mol Imaging. 2024; 51(6): 1703-1712.

Rights & permissions

2026 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.